Patient baseline characteristics (N = 33)
| Baseline characteristic . | Value* . |
|---|---|
| Age, y (range) | 66 (52-82) |
| Male sex, n (%) | 19 (58) |
| Diagnosis to on-study, mo (range) | 37.4 (0.9-104.1) |
| Prior regimens, n (range) | 2 (1-8) |
| Alkylators, n (%) | 30 (91) |
| Corticosteroids, n (%) | 26 (79) |
| IMiDs, n (%) | 7 (21) |
| Proteasome inhibitors, n (%) | 14 (42) |
| Prior hematopoietic stem cell transplantation, n (%) | 16 (48) |
| ECOG performance status > 1, n (%) | 10 (30) |
| NYHA class 1/2, n (%) | 18 (64)/10 (36) |
| Organs involved, n (range) | 1 (0-3) |
| Organ involvement, n (%) | |
| Heart | 27 (82) |
| Kidney | 12 (36) |
| Liver | 1 (3) |
| Autonomic nerve | 2 (6) |
| Peripheral nerve | 6 (18) |
| Clonality, λ/κ (%) | 21 (66)/11 (34) |
| Creatinine, mg/dL (range) | 1.0 (0.7-2.4) |
| Alkaline phosphatase, IU/L (range) | 100 (54-367) |
| Albumin, g/dL (range) | 3.2 (2.1-4.1) |
| Serum troponin, μg/L (range) | 0.01 (0.01-0.12) |
| NT-proBNP, ng/L (range) | 1639 (88-36 498) |
| Troponin T/NT-proBNP stage I /II/III, n (%)† | 3(9)/21 (66)/8 (25) |
| Serum M protein, g/dL (range) | 0 (0-2.0) |
| Urine M protein, mg/24 h (range) | 0 (0-1278) |
| Involved Ig free light chain, mg/dL (range) | 17.6 (4.98-706) |
| Total urine protein, mg/24 h (range) | 181 (22-9433) |
| BM plasma cells, % (range) | 4 (0-56) |
| FISH abnormal, n (%)‡ | 20 (61%) |
| t(11;14), n (%) | 12 (63) |
| Deletion 13q, n (%) | 10 (30) |
| Deletion 17p, n (%) | 2 (11) |
| Other, n (%) | 2 (6) |
| Interventricular septal thickness, mm (range) | 14.5 (9-22) |
| Left ventricular ejection fraction, % (range) | 61 (37-80) |
| Baseline characteristic . | Value* . |
|---|---|
| Age, y (range) | 66 (52-82) |
| Male sex, n (%) | 19 (58) |
| Diagnosis to on-study, mo (range) | 37.4 (0.9-104.1) |
| Prior regimens, n (range) | 2 (1-8) |
| Alkylators, n (%) | 30 (91) |
| Corticosteroids, n (%) | 26 (79) |
| IMiDs, n (%) | 7 (21) |
| Proteasome inhibitors, n (%) | 14 (42) |
| Prior hematopoietic stem cell transplantation, n (%) | 16 (48) |
| ECOG performance status > 1, n (%) | 10 (30) |
| NYHA class 1/2, n (%) | 18 (64)/10 (36) |
| Organs involved, n (range) | 1 (0-3) |
| Organ involvement, n (%) | |
| Heart | 27 (82) |
| Kidney | 12 (36) |
| Liver | 1 (3) |
| Autonomic nerve | 2 (6) |
| Peripheral nerve | 6 (18) |
| Clonality, λ/κ (%) | 21 (66)/11 (34) |
| Creatinine, mg/dL (range) | 1.0 (0.7-2.4) |
| Alkaline phosphatase, IU/L (range) | 100 (54-367) |
| Albumin, g/dL (range) | 3.2 (2.1-4.1) |
| Serum troponin, μg/L (range) | 0.01 (0.01-0.12) |
| NT-proBNP, ng/L (range) | 1639 (88-36 498) |
| Troponin T/NT-proBNP stage I /II/III, n (%)† | 3(9)/21 (66)/8 (25) |
| Serum M protein, g/dL (range) | 0 (0-2.0) |
| Urine M protein, mg/24 h (range) | 0 (0-1278) |
| Involved Ig free light chain, mg/dL (range) | 17.6 (4.98-706) |
| Total urine protein, mg/24 h (range) | 181 (22-9433) |
| BM plasma cells, % (range) | 4 (0-56) |
| FISH abnormal, n (%)‡ | 20 (61%) |
| t(11;14), n (%) | 12 (63) |
| Deletion 13q, n (%) | 10 (30) |
| Deletion 17p, n (%) | 2 (11) |
| Other, n (%) | 2 (6) |
| Interventricular septal thickness, mm (range) | 14.5 (9-22) |
| Left ventricular ejection fraction, % (range) | 61 (37-80) |
ECOG indicates Eastern Cooperative Oncology Group; and IMiDs, immunomodulatory drugs such as thalidomide and lenalidomide.
Values given are medians.
Troponin T/NT-proBNP staging was as follows: using the cutoffs of troponin t of < 0.035 ng/L and NT-proBNP < 332 pg/L, stage I is both below threshold; stage II, one above threshold; and stage III, both above threshold.23
FISH was not performed in 10 patients.